Is Compounded Tirzepatide Still Legal in 2026?

Key takeaways

• Not banned, but narrowly limited. The FDA ended the tirzepatide shortage on December 19, 2024. Shortage-based copies had to stop by March 5, 2025 at pharmacies and March 19, 2025 at outsourcing facilities.
• The courts sided with the FDA. The Fifth Circuit Court of Appeals affirmed the FDA's shortage decision on August 27, 2026.
• Not FDA-approved and not a generic. There is no FDA-approved generic of Zepbound, and the FDA says sellers may not call compounded drugs generic or the same as approved drugs.
• Real safety signals. The FDA had more than 730 adverse event reports tied to compounded tirzepatide as of May 31, 2026, and several compounded tirzepatide products were recalled in fall 2026 over sterility.
• Check before you buy. Use a licensed prescriber and a pharmacy licensed in your state, and avoid "research use only" vials and sellers that skip the prescription.

Is compounded tirzepatide still legal in 2026?

Yes, but only under the federal compounding rules, and those rules got stricter once the shortage ended. Under section 503A of the federal drug law, a state-licensed pharmacy may compound tirzepatide for an individual patient with a prescription. It may not compound "regularly or in inordinate amounts" products that are "essentially copies" of Zepbound or Mounjaro.

A compounded product is not a copy when "a prescriber determines and documents" a change that "produces a significant difference" for "an identified individual patient," according to the FDA's statement updated April 1, 2026. A lower price is not a medical reason. The FDA has also said it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a product in a calendar month.

Outsourcing facilities (section 503B) are different: they may not compound tirzepatide from bulk ingredients, because tirzepatide is neither on the FDA's 503B bulks list nor in shortage. Whatever the route, compounded tirzepatide is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality.

Why did the FDA stop shortage compounding of tirzepatide?

Federal law lets pharmacies make copies of a drug while it is on the FDA's shortage list. Tirzepatide injection went on that list on December 15, 2022, when demand for Mounjaro and later Zepbound outran supply. That is why compounded tirzepatide spread so fast in 2023 and 2024.

On October 2, 2024, the FDA decided the shortage was resolved. A trade group of outsourcing facilities sued, the court sent the decision back to the FDA, and on December 19, 2024 the FDA reached the same conclusion in a formal order, finding that Lilly's supply could meet projected demand. Pharmacies had until February 18, 2025 and outsourcing facilities until March 19, 2025 to wind down. Because the pharmacy deadline was tied to the court case, it ended on March 5, 2025, when the court refused to block the FDA's decision. On August 27, 2026, the Fifth Circuit Court of Appeals affirmed the ruling for the FDA.

Can pharmacies still compound tirzepatide? 503A vs 503B

Yes, state-licensed 503A pharmacies can, within limits; 503B outsourcing facilities cannot use bulk tirzepatide. A 503A pharmacy may use bulk tirzepatide because it is an ingredient of FDA-approved drugs, as long as it comes from an FDA-registered maker with a certificate of analysis. Outsourcing facilities follow federal manufacturing standards and are inspected by the FDA, but in 2026 they may not compound tirzepatide from bulk, and the FDA has proposed to keep it that way. Neither kind of pharmacy makes a compounded product FDA-approved.

Is compounded tirzepatide being banned or going away?

No ban has been issued, but three things could tighten the rules further. First, on April 30, 2026 the FDA proposed to keep tirzepatide, semaglutide and liraglutide off the list of ingredients outsourcing facilities may use; comments closed July 30, 2026, and no final decision had been published as of November 2026. Second, on February 6, 2026 the FDA said it intends to restrict the GLP-1 ingredients used in mass-marketed compounded drugs; we found no rule putting that into effect yet. Third, the FDA keeps warning pharmacies whose "personalized" products look like copies of Zepbound.

The court case is over at the appeals level: the Fifth Circuit affirmed the FDA on August 27, 2026, and we found no request for Supreme Court review as of November 2026.

Is compounded tirzepatide FDA-approved or a generic?

No. Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. It is also not a generic: the FDA says a generic is approved before it is sold, "while a compounded drug is not approved by FDA."

There is no FDA-approved generic of Zepbound. The FDA's drug database lists only Eli Lilly's two tirzepatide products, Mounjaro (type 2 diabetes, approved in 2022) and Zepbound (weight management and sleep apnea, approved in 2023). The FDA has told sellers they cannot describe compounded GLP-1s as generic, "the same as" an FDA-approved drug or "clinically proven," or claim they share the brand's active ingredient. If a website says any of these things, the FDA treats it as a red flag (FDA guidance for telehealth companies).

What is illegal: "research" peptides, no-prescription sellers and counterfeits

Some tirzepatide sold online is illegal no matter what anyone calls it:

• "For research use only" or "not for human consumption" vials sold to people for injection. The FDA has sent warning letters to sellers of these products, including in August 2026, and urges consumers not to buy them.
• Sellers that skip the prescription. Tirzepatide in any form needs a prescription; the FDA lists "does not require a screening and prescription by a licensed doctor" as a red flag.
• Counterfeit pens and fake labels. The FDA has found compounded tirzepatide labels naming pharmacies that do not exist, or a real pharmacy that did not make the product.
• Unapproved look-alikes. The FDA says retatrutide and cagrilintide "cannot be used in compounding under federal law."

These products have unknown ingredients, strength and sterility. Legal compounded tirzepatide comes only with a prescription, from a licensed pharmacy that puts its real name and address on the label.

Is compounded tirzepatide safe?

Nobody can promise that, because the FDA has not reviewed compounded tirzepatide for safety, effectiveness or quality. The FDA says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." As of May 31, 2026, the FDA had received more than 730 adverse event reports tied to compounded tirzepatide and 990 tied to compounded semaglutide. A report does not prove the drug caused the problem, and many problems are never reported.

The FDA's main concerns are dosing errors with multi-dose vials, sterility, ingredient sources and fake products. In an August 12, 2026 letter to state medical boards, the FDA noted that Zepbound comes in fixed single doses, while a compounded vial may hold several doses at a different strength per milliliter, so the volumes "are not interchangeable." The FDA advises discarding a multi-dose vial 28 days after first use and not using a vial that arrives warm. In fall 2026, FDA enforcement reports listed recalls of several compounded tirzepatide products, some with added vitamin B12 or niacinamide, over sterility. Ask your pharmacist how many milliliters equal your prescribed dose, and talk to your provider about any side effect.

What warnings apply to tirzepatide in any form?

The drug in compounded tirzepatide carries the same risks listed on the Zepbound label, and compounded products have no FDA label of their own. Zepbound has a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it does in people. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The label also warns about severe stomach and bowel side effects, kidney injury from dehydration, gallbladder problems, pancreatitis, serious allergic reactions, low blood sugar when used with insulin or sulfonylureas, and breathing in stomach contents during anesthesia. On November 9, 2026, the FDA required all GLP-1 labels to add a warning about NAION, a rare cause of sudden vision loss in one eye. For the full list, see our guide to tirzepatide side effects. Talk to your provider before starting, and report any new symptoms.

How do you check that a compounding pharmacy is legitimate?

Eight checks, in the order you can do them:

What are the red flags of an unsafe tirzepatide seller?

The FDA lists these warning signs. Walk away if a company:

• claims the compounded drug "is the same as an FDA-approved drug," or calls it generic or "clinically proven";
• offers prices "that seem too good to be true";
• does not require a screening and a prescription from a licensed clinician;
• has no licensed clinician to answer questions after your medicine arrives;
• sends a vial with spelling errors, a wrong pharmacy address, or a pharmacy name you think is fake;
• ships medicine that is damaged, warm, or missing instructions;
• sells vials labeled "research use only" or "not for human consumption," or offers retatrutide.

A low price is not proof of a problem, and a high price is not proof of quality. What matters is a real prescriber, a licensed pharmacy you can look up, and a clear label.

Do state laws change the answer?

They can add rules on top of federal law. We found no state law that bans compounded tirzepatide outright, but several state boards spell out the federal limits, and some go further on ingredients. Two state rules apply everywhere: the pharmacy must be licensed or registered to ship into your state, and the prescriber must be licensed in the state where you are during the visit.

Is compounded semaglutide still legal and safe?

The same rules apply, a few weeks later. The FDA declared the semaglutide shortage resolved on February 21, 2025; the grace period ended April 24, 2025 for pharmacies and May 22, 2025 for outsourcing facilities. The same appeals court affirmed the FDA on August 27, 2026, and the April 30, 2026 proposal covers semaglutide too.

One extra issue applies to semaglutide: the FDA says salt forms such as semaglutide sodium and semaglutide acetate "are different active ingredients" and it is "not aware of any lawful basis for their use in compounding." Compounded semaglutide is not FDA-approved and is not Ozempic® or Wegovy®. MaxLife's compounded semaglutide is $89/mo flat.

Where does MaxLife fit?

MaxLife is a telehealth patient management platform, not a pharmacy, manufacturer or compounder. An independent licensed provider reviews your health history, and a prescription is written only if the provider decides it is right for you. The medicine is prepared and dispensed by licensed partner pharmacies, including Dirx Pharmacy, Southend Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Advanced Pharmacy, Perfect Rx Pharmacy, Health Wealth Pharmacy, Quaker Community Pharmacy, VLS Pharmacy and NewLife Rx Pharmacy. MaxLife is LegitScript certified.

Compounded tirzepatide through MaxLife is $120 a month, flat: all-inclusive, the same price at every dose, with no membership fee. It is not FDA-approved. If your insurance covers Zepbound, the brand may cost you less, so check your coverage first; our guide to online tirzepatide providers compares the options.